1 Incredible Reason to Buy LLY's Stock in November

Core Insights - Eli Lilly has secured a deal with the Trump administration that could significantly boost its stock value [1][5] - The company’s drug tirzepatide, marketed as Mounjaro and Zepbound, has become the best-selling drug globally, with year-to-date sales of $24.8 billion [2][10] - The agreement will allow Medicare to cover GLP-1 weight loss drugs at discounted prices, expanding access to millions of recipients [6][10] Company Overview - Eli Lilly's current stock price is $1017.78, with a market capitalization of $962 billion and a gross margin of 83.03% [3] - The company leads the weight-loss drug market with a 57% market share, and the market is projected to exceed $200 billion in annual sales by 2031 [10][11] Market Dynamics - The deal with the Trump administration will lower the cash price of Zepbound from approximately $500 to as low as $150 for eligible Medicare recipients [8] - An estimated 1-in-10 Medicare recipients may qualify for the discounted drugs, which could significantly increase the number of prescriptions [6][9] - The overall number of patients starting GLP-1 treatments for non-diabetic purposes has surged by 700% since 2019, indicating a growing market potential [9] Future Prospects - The agreement is expected to enhance Eli Lilly's position in the expanding weight-loss drug market, with additional eligibility for Medicaid recipients anticipated by 2027 [7][10] - The introduction of a new "TrumpRx" website will facilitate access to these medications at reduced prices [8]